EP2299820A4 - Ophthalmic formulation of rho kinase inhibitor compound - Google Patents

Ophthalmic formulation of rho kinase inhibitor compound

Info

Publication number: EP2299820A4
Authority: EP; European Patent Office
Prior art keywords: kinase inhibitor; inhibitor compound; rho kinase; ophthalmic formulation; ophthalmic
Prior art date: 2008-06-18
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Withdrawn

Application number

EP09767519A

Other languages

German (de)

French (fr)

Other versions

EP2299820A1 (en

Inventor

Lori Richards

Christopher S Crean

Ward M Peterson

Leo Trevino

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Inspire Pharmaceuticals Inc

Original Assignee

Inspire Pharmaceuticals Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-06-18

Filing date

2009-06-11

Publication date

2012-11-14

2009-06-11 Application filed by Inspire Pharmaceuticals Inc filed Critical Inspire Pharmaceuticals Inc

2011-03-30 Publication of EP2299820A1 publication Critical patent/EP2299820A1/en

2012-11-14 Publication of EP2299820A4 publication Critical patent/EP2299820A4/en

Status Withdrawn legal-status Critical Current

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Epidemiology (AREA)
Ophthalmology & Optometry (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)

EP09767519A 2008-06-18 2009-06-11 Ophthalmic formulation of rho kinase inhibitor compound Withdrawn EP2299820A4 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US7351908P	2008-06-18	2008-06-18
PCT/US2009/047108 WO2009155209A1 (en)	2008-06-18	2009-06-11	Ophthalmic formulation of rho kinase inhibitor compound

Publications (2)

Publication Number	Publication Date
EP2299820A1 EP2299820A1 (en)	2011-03-30
EP2299820A4 true EP2299820A4 (en)	2012-11-14

Family

ID=41434400

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EP09767519A Withdrawn EP2299820A4 (en)	2008-06-18	2009-06-11	Ophthalmic formulation of rho kinase inhibitor compound

Country Status (3)

Country	Link
EP (1)	EP2299820A4 (en)
JP (1)	JP2011524912A (en)
WO (1)	WO2009155209A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
BR112013001015A2 (en) *	2010-07-27	2016-05-24	Inspire Pharmaceuticals Inc	method for treating ophthalmic diseases using kinase inhibitor compounds in prodrug forms
EP3183346B1 (en)	2014-08-22	2024-10-23	Auckland Uniservices Limited	Channel modulators
WO2020047229A1 (en)	2018-08-29	2020-03-05	University Of Massachusetts	Inhibition of protein kinases to treat friedreich ataxia
US12048678B2 (en)	2018-10-02	2024-07-30	Case Western Reserve University	Compounds for treating myelin related disorders
WO2024145569A2 (en)	2022-12-30	2024-07-04	Avicenna Biosciences, Inc.	Azaindole rock inhibitors

Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1256574A1 (en) *	2000-02-01	2002-11-13	Kirin Beer Kabushiki Kaisha	Nitrogen-containing compounds having kinase inhibitory activity and drugs containing the same
US20070149548A1 (en) *	2005-12-22	2007-06-28	Alcon Manufacturing, Ltd.	(indazol-5-yl)-pyrazines and (1,3-dihydro-indol-2-one)-pyrazines for treating rho kinase-mediated diseases and conditions

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2502583A1 (en) *	2002-09-12	2004-03-25	Kirin Beer Kabushiki Kaisha	Isoquinoline derivatives having kinase inhibitory activity and medicament containing the same
EP1679308B1 (en) *	2003-10-15	2013-07-24	Ube Industries, Ltd.	Novel indazole derivative
US20050272851A1 (en) *	2004-06-04	2005-12-08	Xerox Corporation	Wax emulsion for emulsion aggregation toner

2009
- 2009-06-11 JP JP2011514714A patent/JP2011524912A/en not_active Withdrawn
- 2009-06-11 WO PCT/US2009/047108 patent/WO2009155209A1/en active Application Filing
- 2009-06-11 EP EP09767519A patent/EP2299820A4/en not_active Withdrawn

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1256574A1 (en) *	2000-02-01	2002-11-13	Kirin Beer Kabushiki Kaisha	Nitrogen-containing compounds having kinase inhibitory activity and drugs containing the same
US20070149548A1 (en) *	2005-12-22	2007-06-28	Alcon Manufacturing, Ltd.	(indazol-5-yl)-pyrazines and (1,3-dihydro-indol-2-one)-pyrazines for treating rho kinase-mediated diseases and conditions

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2009155209A1 *

Also Published As

Publication number	Publication date
JP2011524912A (en)	2011-09-08
EP2299820A1 (en)	2011-03-30
WO2009155209A1 (en)	2009-12-23

Publication	Publication Date	Title
HK1259148A1 (en)	2019-11-29	Compounds useful as inhibitors of atr kinase
ZA201204136B (en)	2013-08-28	Pteridinones as inhibitors of polo-like kinase
IL213906A0 (en)	2011-07-31	Pyrimidinecarboxamide derivatives as inhibitors of syk kinase
HK1161260A1 (en)	2012-08-24	Compounds useful as inhibitors of atr kinase atr
HRP20130698T1 (en)	2013-10-11	Novel phenylpyrazinones as kinase inhibitors
HRP20130787T1 (en)	2013-09-30	Imidazopyridazinecarbonitriles useful as kinase inhibitors
IL218271A0 (en)	2012-04-30	Heterocyclic compounds as janus kinase inhibitors
EP2378875A4 (en)	2013-01-16	Cell-permeant peptide-based inhibitor of kinases
EP2406236A4 (en)	2013-07-24	Rho kinase inhibitors
ZA201100344B (en)	2012-10-31	Pyrimidine derivatives as kinase inhibitors
IL208716B (en)	2018-02-28	Phosphorus derivatives as kinase inhibitors
IL213464A0 (en)	2011-07-31	Kinase inhibitor compounds
EP2336123A4 (en)	2012-05-02	Heterocyclic compound as protein kinase inhibitor
ZA201004942B (en)	2011-12-28	Ptrrolopyrazine kinase inhibitors
EP2234618A4 (en)	2011-04-27	Benzopyrans and analogs as rho kinase inhibitors
HK1151291A1 (en)	2012-01-27	2-benzylpyridazinone derivatives as met kinase inhibitors
IL210573A0 (en)	2011-03-31	Compounds as kinase inhibitors
WO2008036459A8 (en)	2008-07-31	Inhibitors of rho kinase
HK1156306A1 (en)	2012-06-08	Substituted dihydropyrazolones as inhibitors of hif-prolyl-4-hydroxylases hif--4-
EP2470183A4 (en)	2013-05-01	Heterocyclic amide compounds as protein kinase inhibitors
EP2323659A4 (en)	2012-03-14	Compounds useful as inhibitors of protein kinases
IL223131A0 (en)	2013-02-03	Heterocyclic compounds as janus kinase inhibitors
IL220205A0 (en)	2012-07-31	Heterocyclic compounds as janus kinase inhibitors
EP2231152A4 (en)	2011-06-08	Thienopyranones as kinase inhibitors
EP2299820A4 (en)	2012-11-14	Ophthalmic formulation of rho kinase inhibitor compound

Legal Events

Date	Code	Title	Description
2011-02-25	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2011-03-30	17P	Request for examination filed	Effective date: 20101215
2011-03-30	AK	Designated contracting states	Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK TR
2011-03-30	AX	Request for extension of the european patent	Extension state: AL BA RS
2011-09-21	DAX	Request for extension of the european patent (deleted)
2012-11-14	A4	Supplementary search report drawn up and despatched	Effective date: 20121011
2012-11-14	RIC1	Information provided on ipc code assigned before grant	Ipc: A61K 9/08 20060101AFI20121005BHEP Ipc: A61K 31/4545 20060101ALI20121005BHEP Ipc: A61K 31/454 20060101ALI20121005BHEP Ipc: A61K 31/4725 20060101ALI20121005BHEP Ipc: A61K 31/416 20060101ALI20121005BHEP
2013-10-25	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN
2013-11-27	18D	Application deemed to be withdrawn	Effective date: 20130511